Roche says SMA drug meets trial goal
November 11, 2019 at 01:27 AM EST
Roche said on Monday its drug risdiplam helped people with type 2 or 3 spinal muscular atrophy improve their motor function, as the Swiss drugmaker presses ahead with a medicine it sees rivaling Biogen's Spinraza and Novartis's Zolgensma.